Literature DB >> 8390727

The future of therapy for glioblastoma.

P K Kornblith1, W C Welch, M K Bradley.   

Abstract

Effective therapy for malignant gliomas has centered on traditional approaches such as surgery and radiation therapy. Over the past two decades, more innovative approaches involving the use of chemotherapy and immunotherapy have been developed. Although these techniques have improved the quality of survival for many patients, the median survival following diagnosis and adjuvant treatment still remains only about a year. Recently, genetically engineered viruses for gene transduction and targeted cell killing have been used successfully in the experimental treatment of glioblastoma multiforme. We provide a review of the current and possible future therapies for malignant glioma with the belief that molecular biologic and genetic techniques offer the greatest hope of significantly altering the course of disease.

Entities:  

Mesh:

Year:  1993        PMID: 8390727     DOI: 10.1016/0090-3019(93)90041-x

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  12 in total

1.  Therapy of glioblastoma multiforme: a cumulative experience of 10 years.

Authors:  A Obwegeser; M Ortler; M Seiwald; H Ulmer; H Kostron
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

2.  Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas.

Authors:  M C Chamberlain; P Kormanik
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

3.  N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy.

Authors:  Chung Kwon Kim; Atique U Ahmed; Brenda Auffinger; Ilya V Ulasov; Alex L Tobias; Kyung-Sub Moon; Maciej S Lesniak
Journal:  Mol Ther       Date:  2013-07-25       Impact factor: 11.454

4.  Prediction of the anti-glioma therapeutic effects of temozolomide through in vivo molecular imaging of MMP expression.

Authors:  Li Li; Yang Du; Dehui Xiang; Liang Chen; Zhifeng Shi; Jie Tian; Xinjian Chen
Journal:  Biomed Opt Express       Date:  2018-06-20       Impact factor: 3.732

5.  Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

6.  Intergeneric poliovirus recombinants for the treatment of malignant glioma.

Authors:  M Gromeier; S Lachmann; M R Rosenfeld; P H Gutin; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

7.  Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

Authors:  Marc C Chamberlain; Sandra Johnston
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

8.  Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway.

Authors:  R A Gjerset; H Fakhrai; D L Shawler; S Turla; O Dorigo; A Grover-Bardwick; D Mercola; S F Wen; H Collins; H Lin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-03       Impact factor: 2.416

Review 9.  The expanding role of chemotherapy for pediatric supratentorial malignant gliomas.

Authors:  D C Lyden; W P Mason; J L Finlay
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

10.  Inhibitory Effect of IFN-beta, on the Antitumor Activity of Celecoxib in U87 Glioma Model.

Authors:  Eun-Kyoung Kim; Dong-Sup Chung; Hye-Jin Shin; Yong-Kil Hong
Journal:  J Korean Neurosurg Soc       Date:  2009-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.